Development of 2,8-diazaspiro[4.5]decan-3-ones as novel sigma-1 receptor antagonists and evaluation of antihyperalgesic effects
- 9 July 2026
- journal article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 180, 110212
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 34 references indexed in Scilit:
- Next-generation drug conjugates for breast cancer: Clinical prospects and mechanism-based strategies to overcome resistanceDrug Discovery Today, 2026
- E‐52862—A selective sigma‐1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double‐blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathyEuropean journal of pain, 2024
- Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitorsEuropean Journal of Medicinal Chemistry, 2022
- The SAR and action mechanisms of autophagy inhibitors that eliminate drug resistanceEuropean Journal of Medicinal Chemistry, 2022
- Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversionEuropean Journal of Medicinal Chemistry, 2021
- Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspectiveBiochemical Pharmacology, 2020
- Sigma-1 Receptor Antagonists: A New Class of Neuromodulatory Analgesics2017
- Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptorsPsychopharmacology, 2014
- Effects of a Selective Sigma 1 Antagonist Compound on Inflammatory PainInflammation, 2013
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973